CUE, US22978P2056

Cue Biopharma stock follows Q3 revenue drop and wider net loss

Published on 11/19/2026 at 02:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cue Biopharma stock enters a new clinical phase as revenue drops and quarterly losses widen. CUE-401 has started first-in-human dosing.

Clinical progress meets heavier spending

  • Third-quarter revenue fell to USD 132,000 from USD 2.149 million a year earlier.
  • CUE-401 entered first-in-human Phase 1 testing, while CUE-221 showed stronger hive resolution in a high-IgE subgroup.
  • Cash and cash equivalents totaled USD 57.939 million at September 30, 2026.
CUE, US22978P2056, Illustration mit AI erstellt.

On November 16, 2026, Cue Biopharma reported third-quarter results and clinical updates in its Form 8-K filing. Revenue for the quarter ended September 30 fell to USD 132,000 from USD 2.149 million in the year-earlier period, while net loss widened to USD 50.016 million from USD 7.448 million.

Clinical programs move forward

Cue said its CUE-221 Phase 2 study in chronic spontaneous urticaria produced dose-responsive results for complete hive resolution. In a prespecified subgroup with baseline IgE of at least 300 IU/mL, 78 percent of patients receiving 4 mg/kg achieved complete hive resolution at week 12, compared with 0 percent for placebo.

The company also said the FDA cleared the CUE-221 investigational new drug application for food allergy. CUE-401, its autoimmune candidate, entered clinical development with first-in-human dosing in the first cohort of a Phase 1 trial.

Funding remains central

Cash and cash equivalents stood at USD 57.939 million on September 30. Cue also said an amendment to its ImmunoScape license agreement increased its right to receive payments to USD 5.5 million, with installments scheduled from the fourth quarter of 2026 through the fourth quarter of 2027.

Cue Biopharma stock traded at EUR 4.37 on Lang & Schwarz at 23:00 CET on Wednesday, November 18.

Business and competitive focus

Cue Biopharma is a United States clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases. Its portfolio includes CUE-221, an anti-IgE antibody for allergic diseases, and CUE-401, a bispecific cytokine fusion protein for autoimmune disease. The company also develops the Immuno-STAT platform, which is designed to target disease-specific T cells in vivo without broad immune modulation.

Cue Biopharma at a glance

  • Company: Cue Biopharma, Inc.
  • ISIN: US22978P2056
  • Ticker: CUE
  • Home exchange: Nasdaq Capital Market
  • Latest Lang & Schwarz quote: EUR 4.37 at 23:00 CET on Wednesday, November 18, 2026
  • Reported period: Third quarter ended September 30, 2026
  • Sector: Healthcare
  • Industry: Biotechnology

The US equity market remains the relevant home-market environment for Cue Biopharma, alongside the S&P 500.

Find more news and analyses on Cue Biopharma stock.

Disclaimer...
en | US22978P2056 | CUE | boerse | 70533261 | bgmi